TP53 and neoplasm: PUC frequently exhibits alterations in the p53, RB, and DNA damage repair pathways, in addition to a high tumor mutation burden and immune-infiltrated phenotype [73], suggesting its potential responsiveness to ICIs such as pembrolizumab and atezolizumab.